Gangliocytoma

Gangliocytoma is a rare, benign (WHO grade I) tumor of the central nervous system composed of mature, neoplastic ganglion cells (neurons). It is classified under the broader category of neuronal and mixed neuronal-glial tumors. Gangliocytomas most commonly arise in the temporal lobe of the brain but can also occur in other locations within the central nervous system, including the cerebellum, brainstem, spinal cord, and floor of the third ventricle. The ICD-10 classification (D36.1) reflects its benign nature. A well-known variant is dysplastic cerebellar gangliocytoma, also called Lhermitte-Duclos disease, which has distinct clinical and pathological features and is associated with PTEN mutations and Cowden syndrome. Clinical presentation depends on the tumor's location and size. Common symptoms include seizures (particularly temporal lobe epilepsy, which may be drug-resistant), headaches, increased intracranial pressure, and focal neurological deficits. In many cases, patients present with a long history of epilepsy before the tumor is identified. On neuroimaging, gangliocytomas typically appear as well-circumscribed, solid or partially cystic lesions that may show calcification. They generally grow slowly and rarely undergo malignant transformation. The primary treatment for gangliocytoma is surgical resection, which is often curative when complete removal is achieved. Gross total resection is associated with excellent long-term outcomes and significant improvement or resolution of seizures in many patients. Because of the tumor's benign nature and slow growth, adjuvant radiation therapy or chemotherapy is generally not required. In cases where the tumor is not fully resectable due to its location, close clinical and radiological follow-up is recommended. Recurrence after complete resection is uncommon, and the overall prognosis is favorable.

Common questions about Gangliocytoma